​Platelet Aggregation in Human Blood
We’ve expanded our capabilities to support high-quality platelet aggregation studies using human samples—helping you move faster from discovery to decision.
Unexpected effects on platelet function can influence the development of various therapeutics—not just antithrombotic drugs.
Many companies are now assessing platelet aggregation early to gain insights into:
✔ Off-target effects on platelet function
✔ Potential pro-thrombotic or anti-thrombotic liabilities
✔ Mechanism of action for novel therapies
✔ Pharmacodynamic activity and dose selection
✔ Differences between lead candidates​
​
​
🔬 Our capabilities
• PRP (platelet-rich plasma) aggregation assays
• Whole blood impedance aggregometry
• Customized agonist panels: (ADP, ASPI, TRAP, collagen, arachidonic acid, and others) ​​​​​​
​
​
​
​
​
​
​
​
​
​​
​
​
​​
​
​
​​
💡 How we support your program
• Clear pharmacodynamic readouts for candidate selection
• Mechanism-of-action insights
• Flexible study designs tailored to your endpoints
​
âš¡ Why clients choose us
• Rapid turnaround times
• Fresh human samples for physiologically relevant data
• Responsive, collaborative study execution
​
If you're advancing antiplatelet, thrombosis-focused therapies, or biologics let’s talk about how we can support your next study.
​
​
​
​
​Early platelet function data can help pinpoint potential liabilities before they escalate into costly development challenges.
​
​
​​​
